Abstract
Although hormone receptor (HR)-positive breast cancer generally shows a favorable prognosis for endocrine therapy, overcoming its resistance is a major challenge. MET alterations are frequently observed in various cancers and have been reported to play a role in chemotherapy resistance and poor prognosis. We investigated the prognostic values of MET-enriched CTCs, along with cfDNA-derived ESR1 and PIK3CA copy number and mutation status in HR+HER2- metastatic breast cancer (MBC) patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
